Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave Shares Climb 5 Percent on HPV Settlement

NEW YORK, Jan. 13 (GenomeWeb News) - Shares in Third Wave were up 5.26 percent, or $.17, at $3.40 in mid-afternoon trading today after the company said it settled its patent-infringement suit against Digene.


As GenomeWeb News reported this morning, Third Wave and Digene agreed to not sue each other over human papillomavirus products patents for one year. The settlement does not include any license or payment by either company.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.